Head-to-head · WeighScore
Fitstry vs No BS RX
The verdict
No BS RX takes it — 82.8/100 to 61.5/100.
No BS RX grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Twenty-four prices on one public page, four dispensing pharmacies named with street addresses, and a no-intro-rate promise the arithmetic actually supports.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Fitstry | No BS RX |
|---|---|---|
| WeighScore | 61.5/100 | 82.8/100 |
| Grade | C | B− |
| Scorecard rank | #320 | #26 |
| Semaglutide | $179/mo (annual plan, plus a separate fee, compounded) | $179/mo month-to-month (a separate low-dose program is $140) |
| Tirzepatide | $269/mo (annual plan, compounded) | $249/mo month-to-month (a separate low-dose program is $140) |
| Coverage | Coverage not published | Not publicly listed |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Yes | Yes |
Graded #320 · C
Strengths
- Transparent pricing before you commit — compounded semaglutide from $179/mo, tirzepatide from $269/mo, oral GLP-1 from $209/mo (annual plan)
- Free screening with a one-time $99 program fee that is fully refunded if a clinician can't prescribe ('Approved, or Your $99 Back')
- Monthly price bundles a lab panel (CMP, A1c, lipids, TSH), unlimited clinician access, bi-weekly care coaching and a 24/7 Care Line
- Runs under Weightstry, LLC, a LegitScript-certified practice, with a named support email and phone
- Full compounded lineup — weekly injection, daily oral tablet and microdosing options
Where it loses points
- Month-to-month pricing is notably higher than the annual plan ($249 vs $179 semaglutide, $339 vs $269 tirzepatide)
- Compounded semaglutide and tirzepatide only — no brand-name (Wegovy/Zepbound) options
- Framed for women 40+, and serves 49 states rather than all 50 (the excluded state isn't disclosed publicly)
- Works with state-licensed compounding pharmacies but doesn't name a specific pharmacy partner on the Fitstry page
- Compounded GLP-1s are not FDA-reviewed or approved — a different evidence and regulatory tier than brand-name
Graded #26 · B−
Strengths
- Names four dispensing pharmacies with street addresses and telephone numbers — Red Rock Compounding Pharmacy, Health Warehouse, Precision Medicine and Triad Rx
- "No Fake Intro Rate — the price on the page is the ongoing program price" is a named commitment, and the $140 in its hero really is a month-to-month rate on a real product
- Every program row prints "503A pharmacy fulfillment" and "No dose-based price changes" on the table itself
- Six programs across four terms are published with no intake and no account
- A sleep program is priced on the same page, including a diagnostic ring study at $33/mo
Where it loses points
- The same $409 twelve-week block appears under three different monthly rates — an $11 saving against one and a $128 saving against another, styled identically
- The low-dose programs stop at twelve weeks; only the standard programs carry 24- and 52-week rungs
- The Terms name four pharmacies and no operating company
- State availability is not published, and there is no FDA-approved brand lane
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 544 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.